BioCryst Pharmaceuticals
BCRX
#4604
Rank
โ‚น230.14 B
Marketcap
โ‚น905.50
Share price
-1.37%
Change (1 day)
21.68%
Change (1 year)

Revenue for BioCryst Pharmaceuticals (BCRX)

Revenue in 2026 (TTM): โ‚น79.28 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is โ‚น85.50 Billion. In 2025 the company made a revenue of โ‚น78.53 Billion an increase over the revenue in the year 2024 that were of โ‚น38.66 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BioCryst Pharmaceuticals from 1996 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚น79.28 B0.95%
2025 โ‚น78.53 B103.11%
2024 โ‚น38.66 B40.14%
2023 โ‚น27.58 B23.11%
2022 โ‚น22.41 B91.57%
2021 โ‚น11.69 B798.03%
2020 โ‚น1.30 B-62.59%
2019 โ‚น3.48 B141.15%
2018 โ‚น1.44 B-10.2%
2017 โ‚น1.60 B-10.2%
2016 โ‚น1.79 B-44.16%
2015 โ‚น3.20 B271.84%
2014 โ‚น0.86 B-19.45%
2013 โ‚น1.07 B-25.63%
2012 โ‚น1.43 B38.54%
2011 โ‚น1.03 B-62.83%
2010 โ‚น2.79 B-19.23%
2009 โ‚น3.46 B27.31%
2008 โ‚น2.71 B-2.76%
2007 โ‚น2.79 B916.33%
2006 โ‚น0.27 B3925.19%
2005 โ‚น6.83 M1672.84%
2004 โ‚น0.38 M-99.48%
2003 โ‚น74.39 M-12.57%
2002 โ‚น85.09 M-84.19%
2001 โ‚น0.53 B912.23%
2000 โ‚น53.18 M-54.57%
1999 โ‚น0.11 B-58.28%
1998 โ‚น0.28 B495.06%
1997 โ‚น47.15 M-49.55%
1996 โ‚น93.47 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Gilead Sciences
GILD
โ‚น2.870 T 3,257.06%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น4.263 T 4,886.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
โ‚น210.85 B 146.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
โ‚น73.68 B-13.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚น57.56 B-32.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
โ‚น83.59 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
โ‚น62.34 B-27.09%๐Ÿ‡บ๐Ÿ‡ธ USA